ナルコレプシー市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、診断別、治療別、エンドユーザー別、地域別セグメント、競合、2020年～2030年

ナルコレプシーの世界市場規模は2024年に34億3,000万米ドルで、予測期間中のCAGRは7.45%で2030年には52億4,000万米ドルに達すると予測されています。

ナルコレプシーの世界市場は、疾患に対する認知度の向上、診断技術や治療オプションの進歩により、着実な成長を遂げています。ナルコレプシーは、カタプレキシーとして知られる日中の過度の眠気と突発的な筋力低下を特徴とする慢性神経疾患であり、近年認知度が高まり、世界中で診断率が上昇しています。市場開拓の主な要因の一つは、症状管理と患者のQOLを改善する革新的な治療法の開発です。例えば、米国国立神経障害・脳卒中研究所（National Institute of Neurological Disorders and Stroke）は、米国で13万5,000～20万人がナルコレプシーを発症していると推定しています。ストレスレベルの上昇が有病率の増加に寄与しているため、ナルコレプシーと診断された患者数は今後数年で増加すると予想されています。同様に、米国神経学会（American Academy of Neurology）の調査によると、欧州諸国では、有病率は10万人あたり20～67人と幅があります。中枢神経刺激薬などの従来の治療法は、オレキシン受容体作動薬や徐放性製剤などの新しい薬によって補完され、有効性と利便性が向上しています。こうした進歩は、既存の治療法の限界にしばしば苦しむ患者のアンメット・メディカル・ニーズへの対応に役立っています。しかし、他の睡眠障害や神経疾患との症状の重複によるナルコレプシーの過小診断や誤診など、市場は依然として課題に直面しています。このような診断の遅れはタイムリーな治療を妨げ、患者の転帰に悪影響を及ぼす可能性があります。

一部の先進的な治療法は高額であるため、リソースの乏しい環境では患者へのアクセスが制限され、市場全体が限定される可能性があります。地域的には、医療インフラが整備され、睡眠障害に対する認識が高い地域で市場が最も発展しています。一方、新興市場はヘルスケアシステムの改善と診断能力の拡大に伴い、より速い成長が見込まれています。研究開発への投資が増加していることも、個別化医療やナルコレプシー症状をよりよく監視・管理することを目的としたデジタルヘルスソリューションなど、新たな治療アプローチへの道を開いています。ナルコレプシーの世界市場は、診断と治療の選択肢を改善し続ける進歩によって有望な可能性を秘めており、世界中で患者の予後改善と生活の質の向上が期待されています。

主な市場促進要因

睡眠障害の有病率の上昇

主な市場課題

過小診断と誤診

主要市場動向

革新的治療法の出現

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 世界のナルコレプシー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（タイプ1、タイプ2、その他）
  • 診断別（睡眠ポリグラム、反復睡眠潜時検査、その他）
  • 治療別（覚醒剤、抗うつ剤、オキシバナトリウム、その他）
  • エンドユーザー別（病院、診療所、薬局、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第7章 北米のナルコレプシー市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第8章 欧州のナルコレプシー市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第9章 アジア太平洋地域のナルコレプシー市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第10章 南米のナルコレプシー市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第11章 中東・アフリカのナルコレプシー市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第12章 市場力学

• 促進要因
• ナルコレプシーの普及率の増加
• 政府機関による取り組みの拡大
• 課題
• ナルコレプシー薬に関連する副作用。
• ナルコレプシー治療に関連する誤診

第13章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第14章 世界のナルコレプシー市場：SWOT分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Jazz Pharmaceuticals Plc.
• BIOPROJET.
• Arena Pharmaceuticals, Inc.
• Graymark Healthcare, Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG.
• Shire.
• Shionogi Inc.
• Ligand Pharmaceuticals, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Narcolepsy Market was valued at USD 3.43 billion in 2024 and is expected to reach USD 5.24 billion by 2030 with a CAGR of 7.45% during the forecast period. The global narcolepsy market is experiencing steady growth, driven by increasing awareness of the disorder and advancements in diagnostic techniques and treatment options. Narcolepsy, a chronic neurological disorder characterized by excessive daytime sleepiness and sudden muscle weakness known as cataplexy, has gained more recognition in recent years, leading to higher diagnosis rates worldwide. One of the primary factors fueling market growth is the development of innovative therapies that improve symptom management and patient quality of life. For instance, the National Institute of Neurological Disorders and Stroke estimates 135,000 to 200,000 people in the U.S. have narcolepsy. Rising stress levels contribute to increasing prevalence, so the number of diagnosed narcolepsy patients is expected to grow in the coming years. Similarly, according to the study conducted by the American Academy of Neurology, the prevalence of the disease varies from 20 to 67 per 100,000 individuals in European countries. Traditional treatments such as central nervous system stimulants have been supplemented by newer medications, including orexin receptor agonists and extended-release formulations, which offer enhanced efficacy and convenience. These advancements have helped address the unmet medical needs of patients who often struggle with the limitations of existing therapies. However, the market still faces challenges, including the underdiagnosis and misdiagnosis of narcolepsy due to symptom overlap with other sleep disorders or neurological conditions. This delay in diagnosis can hinder timely treatment and negatively impact patient outcomes.

The high cost of some advanced therapies may restrict access for patients in low-resource settings, limiting the overall market reach. Geographically, the market is most developed in regions with well-established healthcare infrastructure and greater awareness of sleep disorders. Meanwhile, emerging markets are expected to witness faster growth as healthcare systems improve and diagnostic capabilities expand. Increasing investment in research and development is also paving the way for novel therapeutic approaches, including personalized medicine and digital health solutions aimed at better monitoring and managing narcolepsy symptoms. The global narcolepsy market holds promising potential as advancements continue to improve diagnosis and treatment options, offering hope for better patient outcomes and enhanced quality of life worldwide.

Key Market Drivers

Rising Prevalence of Sleep Disorders

The rising prevalence of sleep disorders is a significant factor influencing the growth of the global narcolepsy market. Sleep disorders encompass a wide range of conditions that disrupt normal sleep patterns, including insomnia, sleep apnea, restless leg syndrome, and narcolepsy. Among these, narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, sudden muscle weakness (cataplexy), and disrupted nighttime sleep. As awareness of sleep health improves and diagnostic techniques become more sophisticated, more individuals are being identified with these conditions, contributing to a growing patient population seeking medical intervention.Several lifestyle and environmental factors have contributed to the increasing occurrence of sleep disorders worldwide. Modern lifestyles marked by high stress levels, irregular sleep schedules, increased screen time, and urbanization have negatively impacted sleep quality for many people. Additionally, the global rise in comorbid conditions such as obesity, mental health disorders, and cardiovascular diseases-which are closely linked to sleep disturbances-has further fueled the prevalence of sleep-related issues. This broader trend creates a conducive environment for the narcolepsy market as individuals experiencing symptoms are more likely to seek specialized treatment.

From a market perspective, the rising prevalence translates into heightened demand for effective diagnostic tools and therapeutic solutions. Improved screening methods allow for earlier and more accurate diagnosis, enabling timely intervention. As more patients are diagnosed with narcolepsy, pharmaceutical companies and healthcare providers are motivated to develop and offer advanced treatment options tailored to patient needs. This includes innovative drugs that target underlying causes or provide better symptom control, as well as supportive therapies that enhance quality of life. The growing patient pool encourages investment in research and development, further advancing the narcolepsy treatment landscape. Healthcare systems worldwide are also recognizing the economic and social burdens of untreated sleep disorders, prompting initiatives to improve access to care. Overall, the rising prevalence of sleep disorders acts as a crucial driver for the narcolepsy market, fostering growth and innovation aimed at meeting increasing patient demand.

Key Market Challenges

Underdiagnosis and Misdiagnosis

Underdiagnosis and misdiagnosis remain significant challenges impacting the growth and effectiveness of the global narcolepsy market. Narcolepsy is a complex neurological disorder characterized by symptoms such as excessive daytime sleepiness, cataplexy (sudden muscle weakness), and disrupted nighttime sleep. However, these symptoms often overlap with those of other more common conditions, including insomnia, depression, epilepsy, and general fatigue. This similarity frequently leads to confusion among healthcare providers, resulting in delayed or incorrect diagnoses. The underdiagnosis of narcolepsy is widespread, with many patients remaining undiagnosed for years after symptom onset. This delay can have serious consequences on patient quality of life, as untreated symptoms impair daily functioning, cognitive performance, and emotional wellbeing. Moreover, underdiagnosis limits the number of patients receiving appropriate treatment, directly affecting the market size and growth potential for narcolepsy therapies.

Misdiagnosis also poses a critical problem, as patients may be treated for conditions they do not have, leading to ineffective therapy and further deterioration of their condition. The absence of specialized sleep disorder clinics and limited access to advanced diagnostic tools in many regions exacerbate this issue. Additionally, a lack of awareness and training among general practitioners and even some specialists contributes to diagnostic challenges. From a market perspective, overcoming underdiagnosis and misdiagnosis is essential for unlocking the full potential of narcolepsy treatment demand. Improving awareness campaigns, enhancing education for healthcare professionals, and expanding access to reliable diagnostic methods such as polysomnography and multiple sleep latency tests are critical steps. As diagnosis rates improve, more patients will seek treatment, driving innovation and growth in the narcolepsy therapeutics market.

Key Market Trends

Emergence of Innovative Therapies

The emergence of innovative therapies is transforming the global narcolepsy market by offering more effective and patient-friendly treatment options. Traditional narcolepsy treatments primarily focused on managing symptoms like excessive daytime sleepiness and cataplexy through stimulants and sodium oxybate. However, these treatments often had limitations related to side effects, dosing frequency, and variable efficacy, which impacted patient adherence and quality of life. Recent advancements in pharmacology have introduced novel therapies targeting the underlying mechanisms of narcolepsy, particularly the orexin (hypocretin) system, which plays a crucial role in regulating wakefulness. Orexin receptor agonists represent a new class of drugs designed to directly address the root cause of narcolepsy rather than just alleviating symptoms. These innovative agents have demonstrated promising results in clinical trials, showing improved efficacy with fewer side effects compared to conventional medications.

The pharmaceutical companies are developing extended-release formulations of existing drugs, such as once-nightly sodium oxybate, which improve convenience and encourage better adherence by reducing the need for multiple daily doses. This approach enhances patient compliance and overall treatment outcomes. The market is also witnessing the introduction of therapies approved for pediatric use, expanding treatment availability to younger patients who were previously underserved. This broadens the patient base and underscores the importance of inclusive treatment development. The rise of innovative therapies in the narcolepsy market is driving growth by meeting unmet clinical needs and improving patient quality of life. These advancements are encouraging ongoing research and investment, fostering a competitive landscape focused on delivering safer, more effective, and tailored treatment options for narcolepsy patients worldwide.

Key Market Players

• Jazz Pharmaceuticals Plc.
  • BIOPROJET.
  • Arena Pharmaceuticals, Inc.
  • Graymark Healthcare, Inc.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
  • Novartis AG.
• Shire.
• Shionogi Inc.
• Ligand Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Narcolepsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Narcolepsy Market, By Type:

• Type 1
• Type 2
• Others

Narcolepsy Market, By Diagnosis:

• Polysomnogram
• Multiple Sleep Latency Test
• Others

Narcolepsy Market, By Treatment:

• Stimulants
• Antidepressants
• Sodium Oxybate
• Others

Narcolepsy Market, By End User:

• Hospitals
• Clinics
• Retail Pharmacies
• Others

Narcolepsy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Narcolepsy Market.

Available Customizations:

Global Narcolepsy Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Narcolepsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type (Type 1, Type 2, Others)
  • 6.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 6.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 6.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 6.2.5. By Region
  • 6.2.6. By Company (2024)
• 6.3. Market Map

7. North America Narcolepsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type (Type 1, Type 2, Others)
  • 7.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 7.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 7.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Narcolepsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By Treatment
      • 7.3.1.2.4. By End User
  • 7.3.2. Canada Narcolepsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By Treatment
      • 7.3.2.2.4. By End User
  • 7.3.3. Mexico Narcolepsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By Treatment
      • 7.3.3.2.4. By End User

8. Europe Narcolepsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type (Type 1, Type 2, Others)
  • 8.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 8.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 8.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 8.2.5. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Narcolepsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By Treatment
      • 8.3.1.2.4. By End User
  • 8.3.2. Germany Narcolepsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By Treatment
      • 8.3.2.2.4. By End User
  • 8.3.3. United Kingdom Narcolepsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By Treatment
      • 8.3.3.2.4. By End User
  • 8.3.4. Italy Narcolepsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By Treatment
      • 8.3.4.2.4. By End User
  • 8.3.5. Spain Narcolepsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By Treatment
      • 8.3.5.2.4. By End User

9. Asia-Pacific Narcolepsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type (Type 1, Type 2, Others)
  • 9.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 9.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 9.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 9.2.5. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Narcolepsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By Treatment
      • 9.3.1.2.4. By End User
  • 9.3.2. India Narcolepsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By Treatment
      • 9.3.2.2.4. By End User
  • 9.3.3. Japan Narcolepsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By Treatment
      • 9.3.3.2.4. By End User
  • 9.3.4. South Korea Narcolepsy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Diagnosis
      • 9.3.4.2.3. By Treatment
      • 9.3.4.2.4. By End User
  • 9.3.5. Australia Narcolepsy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Type
      • 9.3.5.2.2. By Diagnosis
      • 9.3.5.2.3. By Treatment
      • 9.3.5.2.4. By End User

10. South America Narcolepsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type (Type 1, Type 2, Others)
  • 10.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 10.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 10.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Narcolepsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By Treatment
      • 10.3.1.2.4. By End User
  • 10.3.2. Argentina Narcolepsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By Treatment
      • 10.3.2.2.4. By End User
  • 10.3.3. Colombia Narcolepsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By Treatment
      • 10.3.3.2.4. By End User

11. Middle East and Africa Narcolepsy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Type (Type 1, Type 2, Others)
  • 11.2.2. By Diagnosis (Polysomnogram, Multiple Sleep Latency Test, Others)
  • 11.2.3. By Treatment (Stimulants, Antidepressants, Sodium Oxybate, Others)
  • 11.2.4. By End User (Hospitals, Clinics, Retail Pharmacies, Others)
  • 11.2.5. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Narcolepsy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Type
      • 11.3.1.2.2. By Diagnosis
      • 11.3.1.2.3. By Treatment
      • 11.3.1.2.4. By End User
  • 11.3.2. Saudi Arabia Narcolepsy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Type
      • 11.3.2.2.2. By Diagnosis
      • 11.3.2.2.3. By Treatment
      • 11.3.2.2.4. By End User
  • 11.3.3. UAE Narcolepsy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Type
      • 11.3.3.2.2. By Diagnosis
      • 11.3.3.2.3. By Treatment
      • 11.3.3.2.4. By End User

12. Market Dynamics

• 12.1. Drivers
• 12.1.1 Increase in Prevalence of Narcolepsy
• 12.1.2 Growing Initiatives by Government Organizations
• 12.2. Challenges
• 12.2.1 Adverse effect related to narcolepsy drugs.
• 12.2.2 Misdiagnosis related to narcolepsy treatment

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Narcolepsy Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1 Jazz Pharmaceuticals Plc.
• 16.2 BIOPROJET.
• 16.3 Arena Pharmaceuticals, Inc.
• 16.4 Graymark Healthcare, Inc.
• 16.5 Mylan N.V.
• 16.6 Teva Pharmaceutical Industries Ltd.
• 16.7 Novartis AG.
• 16.8 Shire.
• 16.9 Shionogi Inc.
• 16.10 Ligand Pharmaceuticals, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer